Pharmacogenomics Market Size & Analysis | Report 2021, 2028
The pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028.
The increasing prevalence of chronic diseases is one of the most critical factors driving the growth of the market. Many older adults (>60%) suffer from two or more chronic conditions. Twin studies stated that genes can cause chronic conditions, such as cardiovascular disease (CVDs), diabetes, obesity, RA, Alzheimer's disease (AD), and depression. Using molecular genetic data from genome-wide association studies (GWAS), it is now possible to measure individual-level risks for these chronic diseases. According to the Centers for Disease Control and Prevention (CDC), in 2020, nearly 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions. The increasing incidence of chronic diseases is triggering the demand of pharmacogenomic technologies for developing novel therapies.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pharmacogenomics Market: Strategic Insights
Market Size Value in US$ 7,087.81 million in 2021 Market Size Value by US$ 14,107.80 Million by 2028 Growth rate CAGR of 10.3% from 2021 to 2028 Forecast Period 2021-2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pharmacogenomics Market: Strategic Insights
| Market Size Value in | US$ 7,087.81 million in 2021 |
| Market Size Value by | US$ 14,107.80 Million by 2028 |
| Growth rate | CAGR of 10.3% from 2021 to 2028 |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
North America is likely to dominate the pharmacogenomics market during 2021–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period. The pharmacogenomics market in the US is expected to grow in the coming years due to rising research activities for developing precision medicine to treat cancer, increasing presence of leading biopharmaceutical and pharmaceutical companies, and growing pharmacogenomic research in the country. The adoption rate of pharmacogenomics-based cancer treatment is rising continuously, and the leading market players are introducing several novel products associated with this approach. Also, the support of the regulatory agencies is expected to drive the market in the US during the forecast period. Currently, several clinical trials are investigating pharmacogenomics technology for developing precise medications and improving the overall response rate of the treatment. In May 2021, US Food and Drug Administration (FDA) approved Lumakras (Sotorasib) for a targeted therapy for non-small cell lung cancer patients with tumors that express the G12C mutation in the KRAS gene.
Market Insights
Growing Funding for Pharmacogenomic Research Drives Market Growth
Genomic sequencing is increasingly used in clinical practice, and over the next five years, genomic data from over 60 million patients are expected to be generated within the healthcare system. Pharmacogenomics is rapidly transitioning into clinical practice, and implementation into healthcare systems supported by government investment is totaling over US$ 4 billion in at least 14 countries.
The UK has announced the world’s largest genome project as a part of EURO200 million public–private collaboration between charities and pharma. The country has already developed the largest genome database in the world through the 100,000 genome projects led by Innovate UK as a part of the UK Research and Innovation. The project will fund researchers and industries to combine data and real-world evidence from the UK healthcare services and create new products and services that can diagnose diseases efficiently.
Moreover, in August 2018, Boston Scientific Corporation, a Massachusetts-based company, announced it landed US$ 4.3 million in seed funding and partnered with Veritas Genetics. The funds will support the company’s mission to enter the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.
Technology-Based Insights
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR. The PCR segment is expected to account for the largest share of the pharmacogenomics market during 2021–2028. Polymerase chain reaction (PCR) is a commonly used technology to rapidly produce millions to billions of copies of a specific DNA sample, allowing scientists to take a small sample of DNA and amplify it to a significant enough amount to investigate in detail. The PCR technologies plays a key role in gene cloning and manipulation, DNA cloning, gene mutagenesis, functional analysis of gene, detection of pathogens, and drug resistence assay. Various pharmaceutical and biopharmaceutical companies offer PCR solutions for pharmacogenomic and drug development applications. For instance, Thermo Fisher Scientific, Inc offers real time PCR solutions for the pharmacogenomic application.
Application – Based Insights
Based on application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others. The oncology segment holds a considerable market share and is projected to continue its dominance during the forecast period. Cancer pharmacogenomics has contributed several essential discoveries to current cancer treatment, changing the paradigm of treatment decisions. World Health Organization (WHO) stated that cancer reckoned for roughly 10 million demises in 2020. Furthermore, as per the data of American Cancer Society, the global burden of carcinoma is anticipated to rise to 27.5 million fresh cases and 16.3 million cancer deaths by year 2040. Such high figures denote that the rising incidence of cancer is creating a requirement for primitive diagnosis and preventive cure. There are numerous methods, such as PCR, INAAT, and NGS, to diagnose carcinoma comprehending. The conception of PCR (polymerase chain reaction) led to an enormous advancement in clinical DNA testing. PCR-based methodologies demand straightforward instrumentation and infrastructure, exploit only minute quantities of biological material, and are extensively harmonious with clinical routine. The application of pharmacogenomics in oncology is significant because of the tapered therapeutic index of chemotherapeutic drugs and the risk for life-threatening adverse effects.
End User – Based Insights
Based on end user, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others. The CROs and CDMOs segment holds a considerable market share and is projected to continue its dominance during the forecast period. The contract research organization (CRO) helps various companies and organization by conducting the clinical trial of their developed products and technologies, whereas the contract development and manufacturing organizations (CDMO) assist the companies in development and manufacturing of the products. The CROs offer services, such as project management, database design and build, data entry and validation, clinical trial data management, medicine and disease coding, quality and metric reporting, statistical analysis plans and reports, validation programming, and safety and efficacy summaries and final study reports. CROs also provides some other services such as gene services, cloning services, and expression.
Companies operating in the pharmacogenomics market adopt the inorganic growth strategy to meet the evolving customer demands across the world, which involves acquisitions, mergers, and collaborations with local and international players in the global market.
Pharmacogenomics Market Report Scope
Pharmacogenomics Market – Segmentation
- Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR.
- By application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others.
- Based on end User, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others.
- By Geography, the intradermal injection market is segmented in North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).
F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc; Illumina, Inc; QIAGEN; Agilent Technologies, Inc; Myriad Genetics, Inc; Admera Health; and Dynamic DNA Laboratories are a few companies operating in the pharmacogenomic market.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Technology, Application, and End User
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The global pharmacogenomics market based on technology is segmented into sequencing, PCR, gel electrophoresis, mass spectrometry, microarray, and others. In 2021, the PCR segment held the largest share of the market by technology and it is expected to witness fastest CAGR during 2021 to 2028, due to increasing utilization of this technology at global level.
The global pharmacogenomics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North American area holds the largest market for pharmacogenomics. The United States held the most significant pharmacogenomics market and is expected to grow due to factors such as the increasing prevalence of chronic diseases and growing investments while the technological advancements by key players in pharmacogenomics is also boosting the growth rate in US.
The Asia Pacific region is expected to account for the fastest growth in the pharmacogenomics market. In Japan, India and South Korea, the market is expected to grow owing to the rapid development of research organizations and biopharmaceutical companies.
Several factors are believed to affect pharmacogenomics market in the coming years. Factors such as growing adoption of personalized therapies, increasing prevalence of chronic diseases, and growing funding in this sector are driving the market growth. However, lack of skilled professionals is likely to hamper the growth of the market.
The pharmacogenomics market majorly consists of the players such as F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc.; Illumina, Inc.; QIAGEN; Agilent Technologies, Inc.; Myriad Genetics, Inc.; Admera Health; Dynamic DNA Laboratories among others..
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies. Pharmacogenomics has direct application in the development of personalized medicine by testing single or multiple genes that are related to the disease. The main aim of this technology is to reduce the occurrence of treatment related adverse events and reduction in overall cost of treatment. The growing cases of ADRs and increasing demand of personalized therapies are expected to trigger the growth rate of this segment.
1. Introduction 29
1.1 Scope of the Study. 29
1.2 The Insight Partners Research Report Guidance. 29
1.3 Market Segmentation. 30
1.3.1 Global Pharmacogenomics Market – By Technology. 31
1.3.2 Global Pharmacogenomics Market – By Application. 32
1.3.3 Global Pharmacogenomics Market – By End User. 32
1.3.4 Global Pharmacogenomics Market – By Geography. 32
2. Key Takeaways 34
3. Research Methodology 40
3.1 Coverage. 41
3.2 Secondary Research. 41
3.3 Primary Research. 41
4. Pharmacogenomics Market – Market Landscape 43
4.1 Overview. 43
4.2 PEST Analysis. 43
4.2.1 North America PEST Analysis. 43
4.2.2 Europe PEST Analysis. 44
4.2.3 Asia Pacific PEST Analysis. 44
4.2.4 Middle East And Africa PEST Analysis. 45
4.2.5 South And Central America PEST Analysis. 45
4.3 Experts Opinion. 46
5. Pharmacogenomics Market – Key Market Dynamics 47
5.1 Market Drivers. 47
5.1.1 Increasing Prevalence of Chronic Diseases. 47
5.1.2 Growing Funding for Pharmacogenomics. 47
5.2 Market Restraints. 48
5.2.1 Lack of Skilled Professionals. 48
5.3 Market Opportunities. 48
5.3.1 Increasing Demand for Third Generation Sequencing. 48
5.4 Future Trends. 49
5.4.1 Increasing Demand for Personalized Medicines. 49
6. Pharmacogenomics Market– Global Analysis 50
6.1 Global Pharmacogenomics Market Revenue Forecast and Analysis. 50
6.2 Global Pharmacogenomics Market, By Geography - Forecast and Analysis. 51
6.3 Market Positioning of Key Players. 51
7. Pharmacogenomics Market Revenue and Forecasts To 2028 – Technology 53
7.1 Overview. 53
7.2 Global Pharmacogenomics Market Share by Technology - 2021 & 2028 (%) 53
7.3 Polymerase Chain Reaction. 54
7.3.1 Overview.. 54
7.3.2 Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 54
7.3.3 Real Time PCR.. 55
7.3.3.1 Overview.. 55
7.3.3.2 Real Time PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 55
7.3.4 Standard PCR.. 56
7.3.4.1 Overview.. 56
7.3.4.2 Standard PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 56
7.3.5 Digital PCR.. 56
7.3.5.1 Overview.. 56
7.3.5.2 Digital PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 57
7.4 Sequencing. 58
7.4.1 Overview.. 58
7.4.2 Sequencing: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 59
7.5 Microarray. 60
7.5.1 Overview.. 60
7.5.2 Microarray: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 60
7.6 Gel Electrophoresis. 61
7.6.1 Overview.. 61
7.6.2 Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 61
7.7 Mass Spectrometry. 62
7.7.1 Overview.. 62
7.7.2 Mass Spectrometry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 62
7.8 Others. 63
7.8.1 Overview.. 63
7.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 63
8. Global Pharmacogenomics Market Revenue and Forecasts To 2028– by Application 64
8.1 Overview. 64
8.2 Global Pharmacogenomics Market Share by Application- 2021 & 2028 (%) 64
8.3 Drug Discovery. 65
8.3.1 Overview.. 65
8.3.2 Drug Discovery: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 65
8.4 Oncology. 66
8.4.1 Overview.. 66
8.4.2 Oncology: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 66
8.5 Neurology & Psychiatry. 67
8.5.1 Overview.. 67
8.5.2 Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 67
8.6 Pain Management 68
8.6.1 Overview.. 68
8.6.2 Pain Management: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 68
8.7 Cardiovascular Disease. 69
8.7.1 Overview.. 69
8.7.2 Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 69
8.8 Others. 70
8.8.1 Overview.. 70
8.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 70
9. Pharmacogenomics Market Revenue and Forecasts To 2028 – End User 71
9.1 Overview. 71
9.2 Global Pharmacogenomics Market Share by End User - 2021 & 2028 (%) 71
9.3 Hospitals and Clinics. 72
9.3.1 Overview.. 72
9.3.2 Hospitals and Clinics: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 72
9.4 Biopharmaceutical Companies. 73
9.4.1 Overview.. 73
9.4.2 Biopharmaceuticals Companies: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 73
9.5 CROs and CDMOs. 74
9.5.1 Overview.. 74
9.5.2 CROs and CDMOs: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 74
9.6 Others. 75
9.6.1 Overview.. 75
9.6.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 75
10. Pharmacogenomics Market Revenue and Forecasts to 2028 – Geographical Analysis 76
10.1 North America: Pharmacogenomics Market 76
10.1.1 Overview.. 76
10.1.2 North America: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 77
10.1.3 North America: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 77
10.1.3.1 North America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 78
10.1.4 North America: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 78
10.1.5 North America: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 79
10.1.6 North America: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 79
10.1.6.1 US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 79
10.1.6.1.1 Overview.. 79
10.1.6.1.2 US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 80
10.1.6.1.3 US: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 80
10.1.6.1.3.1 US: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 81
10.1.6.1.4 US: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 81
10.1.6.1.5 US: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 82
10.1.6.2 Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 82
10.1.6.2.1 Overview.. 82
10.1.6.2.2 Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 83
10.1.6.2.3 Canada: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 83
10.1.6.2.3.1 Canada: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 84
10.1.6.2.4 Canada: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 84
10.1.6.2.5 Canada: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 85
10.1.6.3 Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 85
10.1.6.3.1 Overview.. 85
10.1.6.3.2 Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 86
10.1.6.3.3 Mexico: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million) 86
10.1.6.3.3.1 Mexico: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 87
10.1.6.3.4 Mexico: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million) 87
10.1.6.3.5 Mexico: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million) 88
10.2 Europe: Pharmacogenomics Market 89
10.2.1 Overview.. 89
10.2.2 Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 90
10.2.3 Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 90
10.2.3.1 Europe: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 91
10.2.4 Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 91
10.2.5 Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 92
10.2.6 Europe: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 92
10.2.6.1 Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 92
10.2.6.1.1 Overview.. 92
10.2.6.1.2 Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 93
10.2.6.1.3 Germany: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 93
10.2.6.1.3.1 Germany: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 94
10.2.6.1.4 Germany: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 94
10.2.6.1.5 Germany: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 95
10.2.6.2 France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 95
10.2.6.2.1 Overview.. 95
10.2.6.2.2 France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 96
10.2.6.2.3 France: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 96
10.2.6.2.3.1 France: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 97
10.2.6.2.4 France: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 97
10.2.6.2.5 France: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 98
10.2.6.3 UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 98
10.2.6.3.1 Overview.. 98
10.2.6.3.2 UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 99
10.2.6.3.3 UK: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 99
10.2.6.3.3.1 UK: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 100
10.2.6.3.4 UK: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 100
10.2.6.3.5 UK: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 101
10.2.6.4 Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 101
10.2.6.4.1 Overview.. 101
10.2.6.4.2 Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 102
10.2.6.4.3 Italy: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 102
10.2.6.4.3.1 Italy: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 103
10.2.6.4.4 Italy: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 103
10.2.6.4.5 Italy: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 104
10.2.6.5 Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 104
10.2.6.5.1 Overview.. 104
10.2.6.5.2 Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 105
10.2.6.5.3 Spain: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 105
10.2.6.5.3.1 Spain: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 106
10.2.6.5.4 Spain: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 106
10.2.6.5.5 Spain: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 107
10.2.6.6 Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 107
10.2.6.6.1 Overview.. 107
10.2.6.6.2 Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 108
10.2.6.6.3 Rest of Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 108
10.2.6.6.3.1 Rest of Europe: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 109
10.2.6.6.4 Rest of Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 109
10.2.6.6.5 Rest of Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 110
10.3 Asia Pacific Pharmacogenomics Market Revenue and Forecasts To 2028. 111
10.3.1 Overview.. 111
10.3.2 Asia Pacific Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 112
10.3.3 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 112
10.3.3.1 Asia Pacific: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 113
10.3.4 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 113
10.3.5 Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 114
10.3.6 Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 114
10.3.6.1 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 114
10.3.6.1.1 Overview.. 114
10.3.6.1.2 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 115
10.3.6.1.3 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 115
10.3.6.1.3.1 Japan: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 116
10.3.6.1.4 Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 116
10.3.6.1.5 Japan: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 117
10.3.6.2 China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 117
10.3.6.2.1 Overview.. 117
10.3.6.2.2 China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 118
10.3.6.2.3 China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 118
10.3.6.2.3.1 China: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 119
10.3.6.2.4 China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 119
10.3.6.2.5 China: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 120
10.3.6.3 India Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 120
10.3.6.3.1 Overview.. 120
10.3.6.3.2 India: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 121
10.3.6.3.3 India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 121
10.3.6.3.3.1 India: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 122
10.3.6.3.4 India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 122
10.3.6.3.5 India: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 123
10.3.6.4 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 123
10.3.6.4.1 Overview.. 123
10.3.6.4.2 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 124
10.3.6.4.3 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 124
10.3.6.4.3.1 South Korea: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 125
10.3.6.4.4 South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 125
10.3.6.4.5 South Korea: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 126
10.3.6.5 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 126
10.3.6.5.1 Overview.. 126
10.3.6.5.2 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 127
10.3.6.5.3 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 127
10.3.6.5.3.1 Australia: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 128
10.3.6.5.4 Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 128
10.3.6.5.5 Australia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 129
10.3.6.6 Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 129
10.3.6.6.1 Overview.. 129
10.3.6.6.2 Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 130
10.3.6.6.3 Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 130
10.3.6.6.3.1 Rest of Asia Pacific: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 131
10.3.6.6.4 Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 131
10.3.6.6.5 Rest of Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 132
10.4 Middle East & Africa Pharmacogenomics Market Revenue and Forecasts To 2028. 133
10.4.1 Overview.. 133
10.4.2 Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 134
10.4.3 Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 134
10.4.3.1 Middle East & Africa: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 135
10.4.4 Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 135
10.4.5 Middle East & Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 136
10.4.6 Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 136
10.4.6.1 UAE: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 136
10.4.6.1.1 Overview.. 136
10.4.6.1.2 UAE: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 137
10.4.6.1.3 UAE: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 137
10.4.6.1.3.1 UAE: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 138
10.4.6.1.4 UAE: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 138
10.4.6.1.5 UAE: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 139
10.4.6.2 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 139
10.4.6.2.1 Overview.. 139
10.4.6.2.2 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 140
10.4.6.2.3 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 140
10.4.6.2.3.1 Saudi Arabia: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 141
10.4.6.2.4 Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 141
10.4.6.2.5 Saudi Arabia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 142
10.4.6.3 South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 142
10.4.6.3.1 Overview.. 142
10.4.6.3.2 South Africa Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 143
10.4.6.3.3 South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 143
10.4.6.3.3.1 South Africa: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 144
10.4.6.3.4 South Africa: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 144
10.4.6.3.5 South Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 145
10.4.6.4 Rest of Middle East and Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 145
10.4.6.4.1 Overview.. 145
10.4.6.4.2 Rest of Middle East and Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 145
10.4.6.4.3 Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 146
10.4.6.4.3.1 Rest of Middle East & Africa: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 146
10.4.6.4.4 Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 147
10.4.6.4.5 Rest of Middle East and Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 147
10.5 South And Central America Pharmacogenomics Market Revenue and Forecasts To 2028. 149
10.5.1 Overview.. 149
10.5.2 South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 150
10.5.3 South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 150
10.5.3.1 South and Central America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 151
10.5.4 South and Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 151
10.5.5 South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 152
10.5.6 South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 152
10.5.6.1 Argentina Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 152
10.5.6.1.1 Overview.. 152
10.5.6.1.2 Argentina Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 153
10.5.6.1.3 Argentina: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 153
10.5.6.1.3.1 Argentina: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 154
10.5.6.1.4 Argentina: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 154
10.5.6.1.5 Argentina: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 155
10.5.6.2 Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 155
10.5.6.2.1 Overview.. 155
10.5.6.2.2 Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 156
10.5.6.2.3 Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 156
10.5.6.2.3.1 Brazil: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 157
10.5.6.2.4 Brazil: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 157
10.5.6.2.5 Brazil: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 158
10.5.6.3 Rest of South and Central America: Pharmacogenomics Market– Revenue and Forecast to 2028 (USD Mn) 158
10.5.6.3.1 Overview.. 158
10.5.6.3.2 Rest of South and Central America: Pharmacogenomics Market– Revenue and Forecast to 2028 (USD Mn) 159
10.5.6.3.3 Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 159
10.5.6.3.3.1 Rest of South & Central America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million) 160
10.5.6.3.4 Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts To 2028, By Application (US$ Million) 160
10.5.6.3.5 Rest of South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 161
11. Impact of COVID-19 Pandemic on Global Pharmacogenomics Market 162
11.1 North America: Impact Assessment of COVID-19 Pandemic. 162
11.2 Europe: Impact Assessment of COVID-19 Pandemic. 163
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic. 164
11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic. 165
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic. 166
12. Industry Landscape 167
12.1 Overview. 167
12.2 Growth Strategies in the Pharmacogenomics Market 167
12.3 Organic Developments. 168
12.3.1 Overview.. 168
12.4 Inorganic Developments. 170
12.4.1 Overview.. 170
13. Company Profiles 172
13.1 Abbott 172
13.1.1 Key Facts. 172
13.1.2 Business Description. 172
13.1.3 Products and Services. 172
13.1.4 Financial Overview.. 173
13.1.5 SWOT Analysis. 174
13.1.6 Key Developments. 175
13.2 F. HOFFMANN-LA ROCHE LTD. 176
13.2.1 Key Facts. 176
13.2.2 Business Description. 176
13.2.3 Products and Services. 176
13.2.4 Financial Overview.. 177
13.2.5 SWOT Analysis. 179
13.2.6 Key Developments. 179
13.3 Oxford Nanopore Technologies. 180
13.3.1 Key Facts. 180
13.3.2 Business Description. 180
13.3.3 Products and Services. 180
13.3.4 Financial Overview.. 180
13.3.5 SWOT Analysis. 181
13.3.6 Key Developments. 181
13.4 THERMO FISHER SCIENTIFIC INC. 182
13.4.1 Key Facts. 182
13.4.2 Business Description. 182
13.4.3 Products and Services. 182
13.4.4 Financial Overview.. 183
13.4.5 SWOT Analysis. 184
13.4.6 Key Developments. 185
13.5 Illumina, Inc. 186
13.5.1 Key Facts. 186
13.5.2 Business Description. 186
13.5.3 Products and Services. 187
13.5.4 Financial Overview.. 187
13.5.5 SWOT Analysis. 188
13.5.6 Key Developments. 189
13.6 QIAGEN. 190
13.6.1 Key Facts. 190
13.6.2 Business Description. 190
13.6.3 Products and Services. 190
13.6.4 Financial Overview.. 191
13.6.5 SWOT Analysis. 192
13.6.6 Key Developments. 193
13.7 Agilent Technologies, Inc. 194
13.7.1 Key Facts. 194
13.7.2 Business Description. 194
13.7.3 Products and Services. 195
13.7.4 Financial Overview.. 195
13.7.5 SWOT Analysis. 197
13.7.6 Key Developments. 197
13.8 Myriad Genetics, Inc. 198
13.8.1 Key Facts. 198
13.8.2 Business Description. 198
13.8.3 Products and Services. 198
13.8.4 Financial Overview.. 199
13.8.5 SWOT Analysis. 200
13.8.6 Key Developments. 200
13.9 Admera Health. 201
13.9.1 Key Facts. 201
13.9.2 Business Description. 201
13.9.3 Products and Services. 201
13.9.4 Financial Overview.. 201
13.9.5 SWOT Analysis. 202
13.9.6 Key Developments. 202
13.10 Dynamic DNA Laboratories. 203
13.10.1 Key Facts. 203
13.10.2 Business Description. 203
13.10.3 Products and Services. 203
13.10.4 Financial Overview.. 203
13.10.5 SWOT Analysis. 204
13.10.6 Key Developments. 204
14. Appendix 205
14.1 About The Insight Partners. 205
14.2 Glossary of Terms. 205
LIST OF TABLES
Table 1. North America Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 77
Table 2. North America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 78
Table 3. North America Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (USD Million) 78
Table 4. US Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 80
Table 5. US Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 81
Table 6. US Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 81
Table 7. US Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 82
Table 8. Canada: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 83
Table 9. Canada: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 84
Table 10. Canada Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 84
Table 11. Canada Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 85
Table 12. Mexico: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 86
Table 13. Mexico: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 87
Table 14. Mexico Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 87
Table 15. Mexico Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 88
Table 16. Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 90
Table 17. Europe: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 91
Table 18. Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 91
Table 19. Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 92
Table 20. Germany: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 93
Table 21. Germany: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 94
Table 22. Germany: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 94
Table 23. Germany: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 95
Table 24. France: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 96
Table 25. France: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 97
Table 26. France: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 97
Table 27. France: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 98
Table 28. UK: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 99
Table 29. UK: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 100
Table 30. UK: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 100
Table 31. UK: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 101
Table 32. Italy: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 102
Table 33. Italy: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 103
Table 34. Italy: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 103
Table 35. Italy: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 104
Table 36. Spain: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 105
Table 37. Spain: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 106
Table 38. Spain: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 106
Table 39. Spain: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 107
Table 40. Rest of Europe: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million) 108
Table 41. Rest of Europe: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 109
Table 42. Rest of Europe: Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million) 109
Table 43. Rest of Europe: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 110
Table 44. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million). 112
Table 45. Asia Pacific: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 113
Table 46. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 113
Table 47. Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 114
Table 48. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 115
Table 49. Japan: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 116
Table 50. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 116
Table 51. Japan: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 117
Table 52. China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 118
Table 53. China: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 119
Table 54. China: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 119
Table 55. China: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 120
Table 56. India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 121
Table 57. India: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 122
Table 58. India: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 122
Table 59. India: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 123
Table 60. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 124
Table 61. South Korea: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 125
Table 62. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 125
Table 63. South Korea: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 126
Table 64. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 127
Table 65. Australia: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 128
Table 66. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 128
Table 67. Australia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 129
Table 68. Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 130
Table 69. Rest of Asia Pacific: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 131
Table 70. Rest of Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 131
Table 71. Rest of Asia Pacific: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 132
Table 72. Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 134
Table 73. Middle East & Africa: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 135
Table 74. Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 135
Table 75. Middle East & Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 136
Table 76. UAE: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 137
Table 77. UAE: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 138
Table 78. UAE: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 138
Table 79. UAE: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 139
Table 80. Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 140
Table 81. Saudi Arabia: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 141
Table 82. Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 141
Table 83. Saudi Arabia: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 142
Table 84. South Africa Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 143
Table 85. South Africa: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 144
Table 86. South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 144
Table 87. South Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 145
Table 88. Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 146
Table 89. Rest of Middle East & Africa: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 146
Table 90. Rest of Middle East & Africa: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 147
Table 91. Rest of Middle East and Africa: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 147
Table 92. South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 150
Table 93. South and Central America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 151
Table 94. South and Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 151
Table 95. South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 152
Table 96. Argentina: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 153
Table 97. Argentina: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 154
Table 98. Argentina: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 154
Table 99. Argentina: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 155
Table 100. Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 156
Table 101. Brazil: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 157
Table 102. Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 157
Table 103. Brazil: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 158
Table 104. Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Technology (US$ Million) 159
Table 105. Rest of South & Central America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million) 160
Table 106. Rest of South & Central America: Pharmacogenomics Market Revenue and Forecasts to 2028, By Application (US$ Million) 160
Table 107. Rest of South and Central America: Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million) 161
Table 108. Organic Developments Done By Companies. 168
Table 109. Inorganic Developments Done By Companies. 170
Table 110. Glossary of Terms. 205
LIST OF FIGURES
Figure 1. Pharmacogenomics Market Segmentation. 30
Figure 2. Pharmacogenomics Market, By Region. 31
Figure 3. Global Pharmacogenomics Market Overview. 34
Figure 4. PCR Segment Held Largest Share of Technology Segment in Pharmacogenomics Market 35
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period. 36
Figure 6. Pharmacogenomics Market, by Geography (US$ Million) 37
Figure 7. Global Pharmacogenomics Market- Leading Country Markets (US$ Million) 38
Figure 8. Global Pharmacogenomics Market, Industry Landscape. 39
Figure 9. North America: PEST Analysis. 43
Figure 10. Europe: PEST Analysis. 44
Figure 11. Asia Pacific: PEST Analysis. 44
Figure 12. Middle East And Africa: PEST Analysis. 45
Figure 13. South And Central America: PEST Analysis. 45
Figure 14. Experts Opinion. 46
Figure 15. Global Pharmacogenomics Market– Revenue Forecast and Analysis – 2021 - 2028. 50
Figure 16. Global Pharmacogenomics Market – By Geography Forecast and Analysis – 2021 - 2028. 51
Figure 17. Market Positioning of Key Players in Global Pharmacogenomics Market 51
Figure 18. Global Pharmacogenomics Market Share by Segment - 2021 & 2028 (%) 53
Figure 19. Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 54
Figure 20. Real Time PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 55
Figure 21. Standard PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 56
Figure 22. Digital PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 57
Figure 23. Sequencing: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 59
Figure 24. Microarray: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 60
Figure 25. Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 61
Figure 26. Mass Spectrometry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 62
Figure 27. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 63
Figure 28. Global Pharmacogenomics Market Share by Application- 2021 & 2028 (%) 64
Figure 29. Drug Discovery: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 65
Figure 30. Oncology: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 66
Figure 31. Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 67
Figure 32. Pain Management: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 68
Figure 33. Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 69
Figure 34. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 70
Figure 35. Global Pharmacogenomics Market Share by End User - 2021 & 2028 (%) 71
Figure 36. Hospital and Clinics: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 72
Figure 37. Biopharmaceutical Companies: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 73
Figure 38. CROs and CDMOs: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 74
Figure 39. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million) 75
Figure 40. North America: Pharmacogenomics Market, by Key Country – Revenue (2021) (US$ Million) 76
Figure 41. North America Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 77
Figure 42. North America: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 79
Figure 43. US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 80
Figure 44. Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 83
Figure 45. Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 86
Figure 46. Europe: Pharmacogenomics Market, by Key Country – Revenue (2021) (US$ Million) 89
Figure 47. Europe: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million) 90
Figure 48. Europe: Pharmacogenomics Market, by Country, 2021 & 2028 (%) 92
Figure 49. Germany: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 93
Figure 50. France: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 96
Figure 51. UK: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 99
Figure 52. Italy: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 102
Figure 53. Spain: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 105
Figure 54. Rest of Europe: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 108
Figure 55. Asia Pacific Pharmacogenomics Market Overview, by Country (2021) 111
Figure 56. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 112
Figure 57. Asia Pacific: Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 114
Figure 58. Japan: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 115
Figure 59. China: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 118
Figure 60. India: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 121
Figure 61. South Korea: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 124
Figure 62. Australia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 127
Figure 63. Rest of Asia Pacific: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million) 130
Figure 64. Middle East & Africa Pharmacogenomics Market Revenue Overview, by Country, 2021 (US$ Million) 133
Figure 65. Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 134
Figure 66. Middle East & Africa Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 136
Figure 67. UAE: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 137
Figure 68. Saudi Arabia: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 140
Figure 69. South Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 143
Figure 70. Rest of Middle East and Africa: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 146
Figure 71. South and Central America Pharmacogenomics Market Revenue Overview, by Country, 2021 (US$ Million) 149
Figure 72. South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 150
Figure 73. South and Central America Pharmacogenomics Market Revenue and Forecasts to 2028, By Country (%) 152
Figure 74. Argentina Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 153
Figure 75. Brazil: Pharmacogenomics Market Revenue and Forecasts to 2028 (US$ Million) 156
Figure 76. Rest of South and Central America: Pharmacogenomics Market– Revenue and Forecast to 2028 (USD Mn) 159
Figure 77. Impact of COVID-19 Pandemic in North America Country Markets. 162
Figure 78. Impact of COVID-19 Pandemic on Sequencing Reagents Market in European Countries. 163
Figure 79. Impact of COVID-19 Pandemic in Asia Pacific Country Markets. 164
Figure 80. Impact of COVID-19 Pandemic on Sequencing Reagents Market in Rest of the World. 165
Figure 81. Impact of COVID-19 Pandemic in South and Central America Country Markets. 166
Figure 82. Growth Strategies in the Pharmacogenomics Market 167
The List of Companies - Pharmacogenomics Market
- F. Hoffmann-la Roche Ltd
- Abbott
- Oxford Nanopore Technologies
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- Admera Health
- Dynamic DNA Laboratories
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For